BR112016002001A2 - Medicamento compreendendo anticorpo antifosfolipase d4 - Google Patents
Medicamento compreendendo anticorpo antifosfolipase d4Info
- Publication number
- BR112016002001A2 BR112016002001A2 BR112016002001A BR112016002001A BR112016002001A2 BR 112016002001 A2 BR112016002001 A2 BR 112016002001A2 BR 112016002001 A BR112016002001 A BR 112016002001A BR 112016002001 A BR112016002001 A BR 112016002001A BR 112016002001 A2 BR112016002001 A2 BR 112016002001A2
- Authority
- BR
- Brazil
- Prior art keywords
- phospholipase
- present application
- antibody
- drug
- pld4
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/573—Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/90—Enzymes; Proenzymes
- G01N2333/914—Hydrolases (3)
- G01N2333/916—Hydrolases (3) acting on ester bonds (3.1), e.g. phosphatases (3.1.3), phospholipases C or phospholipases D (3.1.4)
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Biochemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Microbiology (AREA)
- General Physics & Mathematics (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- Pathology (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Transplantation (AREA)
- Pulmonology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Enzymes And Modification Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
MEDICAMENTO COMPREENDENDO ANTICORPO ANTIFOSFOLIPASE D4. O presente pedido fornece os medicamentos compreendendo os anticorpos que se ligam à fosfolipase D4(PLD4) assim como um método usando os ditos medicamentos para detectar e suprimir células B ativadas. O presente pedido é direcionado ainda à terapia de doenças autoimunes e alérgicas, resultando da função ativo-repressora. De modo a resolver estes problemas, o presente pedido fornece um anticorpo monoclonal que se liga ao domínio extracelular da proteína da fosfolipase D4 (PLD4), ou um fragmento contendo uma região de ligação de antígeno do mesmo como um ingrediente ativo.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2013158258 | 2013-07-30 | ||
| JP2013-158258 | 2013-07-30 | ||
| PCT/JP2014/070661 WO2015016386A1 (en) | 2013-07-30 | 2014-07-30 | Medicament comprising anti-phospholipase d4 antibody |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| BR112016002001A2 true BR112016002001A2 (pt) | 2017-08-29 |
| BR112016002001B1 BR112016002001B1 (pt) | 2023-04-25 |
Family
ID=51493000
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112016002001-4A BR112016002001B1 (pt) | 2013-07-30 | 2014-07-30 | Uso de anticorpo monoclonal, método in vitro para detectar células b ativadas, reagente para detectar células b ativadas, método in vitro para suprimir a atividade b das células ativadas, e anticorpo monoclonal |
Country Status (17)
| Country | Link |
|---|---|
| US (2) | US20160168266A1 (pt) |
| EP (1) | EP3027656B1 (pt) |
| JP (3) | JP6431523B2 (pt) |
| KR (1) | KR102367760B1 (pt) |
| CN (1) | CN105745226B (pt) |
| AU (1) | AU2014297217B2 (pt) |
| BR (1) | BR112016002001B1 (pt) |
| CA (1) | CA2919736C (pt) |
| DK (1) | DK3027656T3 (pt) |
| ES (1) | ES2736324T3 (pt) |
| HU (1) | HUE044469T2 (pt) |
| MX (1) | MX2016001193A (pt) |
| PL (1) | PL3027656T3 (pt) |
| RU (1) | RU2709741C2 (pt) |
| SG (2) | SG11201600666SA (pt) |
| TR (1) | TR201910330T4 (pt) |
| WO (1) | WO2015016386A1 (pt) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2809683B1 (en) * | 2012-01-31 | 2018-10-03 | SBI Biotech Co., Ltd. | Anti-phospholipase d4 antibody |
| CN117330747A (zh) * | 2016-07-15 | 2024-01-02 | 武田药品工业株式会社 | 用于评估对于成浆细胞和浆细胞耗竭性疗法的应答的方法和材料 |
| JP7140367B2 (ja) * | 2018-05-31 | 2022-09-21 | 国立大学法人 東京大学 | ヒト由来サンプルにおける可溶型ｔｌｒ７の分析 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MD1367C2 (ro) * | 1992-11-13 | 2000-11-30 | Idec Pharmaceuticals Corporation | Metode de tratament al limfomului celulelor B, anticorpi anti-CD20, hibridom. |
| EP1107978A1 (en) * | 1998-08-24 | 2001-06-20 | Alphagene, Inc. | Secreted proteins and polynucleotides encoding them |
| WO2002045570A2 (en) * | 2000-12-07 | 2002-06-13 | Millennium Pharmaceuticals, Inc. | Methods and compositions for the diagnosis and treatment of viral disease using 55092 |
| JP2013052781A (ja) | 2011-09-05 | 2013-03-21 | Tokai Rika Co Ltd | 車両用ミラー装置 |
| EP2809683B1 (en) * | 2012-01-31 | 2018-10-03 | SBI Biotech Co., Ltd. | Anti-phospholipase d4 antibody |
-
2014
- 2014-07-30 BR BR112016002001-4A patent/BR112016002001B1/pt active IP Right Grant
- 2014-07-30 AU AU2014297217A patent/AU2014297217B2/en active Active
- 2014-07-30 ES ES14761423T patent/ES2736324T3/es active Active
- 2014-07-30 CN CN201480047721.6A patent/CN105745226B/zh active Active
- 2014-07-30 KR KR1020167002746A patent/KR102367760B1/ko active IP Right Grant
- 2014-07-30 WO PCT/JP2014/070661 patent/WO2015016386A1/en active Application Filing
- 2014-07-30 HU HUE14761423 patent/HUE044469T2/hu unknown
- 2014-07-30 PL PL14761423T patent/PL3027656T3/pl unknown
- 2014-07-30 CA CA2919736A patent/CA2919736C/en active Active
- 2014-07-30 RU RU2016106708A patent/RU2709741C2/ru active
- 2014-07-30 TR TR2019/10330T patent/TR201910330T4/tr unknown
- 2014-07-30 EP EP14761423.4A patent/EP3027656B1/en active Active
- 2014-07-30 US US14/908,004 patent/US20160168266A1/en not_active Abandoned
- 2014-07-30 SG SG11201600666SA patent/SG11201600666SA/en unknown
- 2014-07-30 MX MX2016001193A patent/MX2016001193A/es unknown
- 2014-07-30 SG SG10201800592SA patent/SG10201800592SA/en unknown
- 2014-07-30 DK DK14761423.4T patent/DK3027656T3/da active
- 2014-07-30 JP JP2016503264A patent/JP6431523B2/ja active Active
-
2018
- 2018-11-01 JP JP2018206702A patent/JP2019014759A/ja not_active Ceased
-
2019
- 2019-09-25 JP JP2019173621A patent/JP6843449B2/ja active Active
-
2020
- 2020-12-18 US US17/127,202 patent/US20210130493A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| EP3027656B1 (en) | 2019-06-26 |
| WO2015016386A1 (en) | 2015-02-05 |
| HUE044469T2 (hu) | 2019-10-28 |
| MX2016001193A (es) | 2016-05-26 |
| AU2014297217B2 (en) | 2020-01-16 |
| CN105745226A (zh) | 2016-07-06 |
| JP6431523B2 (ja) | 2018-11-28 |
| ES2736324T3 (es) | 2019-12-27 |
| CA2919736C (en) | 2022-03-22 |
| JP2019014759A (ja) | 2019-01-31 |
| RU2016106708A3 (pt) | 2018-03-30 |
| US20160168266A1 (en) | 2016-06-16 |
| TR201910330T4 (tr) | 2019-07-22 |
| RU2709741C2 (ru) | 2019-12-19 |
| US20210130493A1 (en) | 2021-05-06 |
| BR112016002001B1 (pt) | 2023-04-25 |
| KR102367760B1 (ko) | 2022-02-24 |
| CN105745226B (zh) | 2020-03-06 |
| JP2019214621A (ja) | 2019-12-19 |
| JP2016534022A (ja) | 2016-11-04 |
| KR20160034934A (ko) | 2016-03-30 |
| CA2919736A1 (en) | 2015-02-05 |
| JP6843449B2 (ja) | 2021-03-17 |
| RU2016106708A (ru) | 2017-09-01 |
| SG11201600666SA (en) | 2016-02-26 |
| EP3027656A1 (en) | 2016-06-08 |
| DK3027656T3 (da) | 2019-08-05 |
| SG10201800592SA (en) | 2018-03-28 |
| AU2014297217A1 (en) | 2016-02-18 |
| PL3027656T3 (pl) | 2019-10-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112015027385A2 (pt) | Anticorpos modificados de ligação ao fcrn humano e métodos de uso | |
| BR112019023754A2 (pt) | anticorpo anti-sirpalpha ou um fragmento de ligação ao antígeno do mesmo, composição farmacêutica, e, combinação do anticorpo anti-sirpalpha ou da composição farmacêutica. | |
| BR112016011401A2 (pt) | moduladores de aplnr e utilizações dos mesmos | |
| BR112018009064A8 (pt) | anticorpo de pd-l1, fragmento de ligação ao antígeno do mesmo e aplicação médica do mesmo | |
| BR112017027778A2 (pt) | anticorpos para o fator xi e métodos de uso | |
| BR112015023262B8 (pt) | Anticorpo isolado, imunoconjugado, formulação farmacêutica e usos do anticorpo | |
| BR112017005110A2 (pt) | anticorpo monoclonal isolado ou fragmento de ligação ao antígeno do mesmo, molécula isolada de ácido nucleico, composição farmacêutica, e, método para diminuir níveis de glicose no sangue ou para tratar uma condição ou doença. | |
| BR112017006178A2 (pt) | região fc, anticorpos, formulação farmacêutica e usos dos anticorpos | |
| CR20130621A (es) | Anticuerpos anti-angptl3 y usos de los mismos | |
| CR20140585A (es) | Proteinas de union a antigeno st2 | |
| BR112015021979A2 (pt) | Anticorpos humanos para grem1 | |
| EA201692458A1 (ru) | Анти-gitr антитела и способы их применения | |
| BR112014031689A2 (pt) | anticorpos reativos cruzados anti-jagged 1/jagged 2, anticorpos anti-jagged ativáveis e métodos de uso deles | |
| BR112014018561A8 (pt) | Anticorpo; ácido nucleico; célula hospedeira; composição farmacêutica; uso de um anticorpo; método para produção de um anticorpo; e método para produção de uma linhagem celular que produz um anticorpo | |
| ECSP12012272A (es) | Proteínas que se unen al tnf-? | |
| BR112014021081A2 (pt) | anticorpos para a metaloproteinase da matriz 9 | |
| BR112015007672A2 (pt) | anticorpos anti-pd-l1 monoclonais humanos e métodos de uso | |
| BR112016007112A2 (pt) | Anticorpos que se ligam a angiopoietina 2 (ang-2) humana, usos de um anticorpo que se liga a angiopoietina 2 (ang-2) humana e combinação | |
| BR112016001782A2 (pt) | Proteína de fusão terapêutica | |
| BR112019008417A2 (pt) | compostos de peptídeo tirosina-tirosina cíclico acoplados a anticorpo como moduladores de receptores de neuropeptídeo y | |
| BR112016013960A2 (pt) | anticorpos, ácido nucleico, célula hospedeira, método de produção de um anticorpo, formulação farmacêutica, uso do anticorpo, método de tratamento e método de ativação de um complexo | |
| BR112015004875A2 (pt) | formulações de anticorpo e seus usos | |
| BR112019005139A2 (pt) | anticorpos anti-il-33 e usos dos mesmos | |
| BR112015030356A2 (pt) | métodos de tratamento de uma taupatia | |
| BR112019010903A2 (pt) | estrutura de cristal de gremlin-1 e anticorpo inibidor |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] |
Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI |
|
| B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
| B06A | Patent application procedure suspended [chapter 6.1 patent gazette] | ||
| B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
| B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 30/07/2014, OBSERVADAS AS CONDICOES LEGAIS |